Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea

NCT06785818 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06785818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06785818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
March 12, 2025
Completion date
December 30, 2039
Enrollment
500 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, diffuse large b-cell lymphoma, follicular lymphoma